| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/08/2006 | CN1744883A Method of obtaining cochlear structures, vaccine compositions, adjuvants and intermediates thereof |
| 03/08/2006 | CN1744874A Composition for preventive treatment of herpessimplex |
| 03/08/2006 | CN1744827A Novel compositions comprising carotenoids |
| 03/08/2006 | CN1744822A Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors |
| 03/08/2006 | CN1743337A Taxol derivative and its pharmaceutical composition |
| 03/08/2006 | CN1743010A Medical penetrant |
| 03/08/2006 | CN1743009A Medicine carrier pseudoglucoprotein nano particle of double-target anti-liver-fibrosis and its preparing method |
| 03/08/2006 | CN1743008A Method for preparing nano liver-target biodegradating medicine carrier material |
| 03/08/2006 | CN1743007A Inflammation-resistant modified imvite and preparing method thereof |
| 03/08/2006 | CN1742997A Mimetics of interleukin-8 and use of them in the prevention, treatment, diagnosis of a disease |
| 03/08/2006 | CN1742708A Transdermal administration pressure-sensitive gel composite substrate |
| 03/08/2006 | CN1742707A Oil-soluble medicine degradable polymer microcapsule injecta and preparing method |
| 03/08/2006 | CN1742706A Water-soluble medicine degradable polymer microcapsule injecta and preparing method |
| 03/08/2006 | CN1244376C Releasable bond and composition containing said bond |
| 03/08/2006 | CN1244327C Thebaic analgesic with controllable release of active content |
| 03/08/2006 | CN1244321C Gastric 5-fluorouracil double slow release tablet of float and stay type for treating gastric cancer |
| 03/08/2006 | CN1244320C Nose spray agent |
| 03/07/2006 | US7009034 Biodegradable hydrogel having a visualization agent that reflects or emits light at a wavelength detectable to a human eyeast partially disposed within the interior. |
| 03/07/2006 | US7009033 With one hydroxy and one carboxylic acid end group produced by living anionic polymerization; carriers for drug delivery or diagnostic reagents. |
| 03/07/2006 | US7008961 Composition and method for treating carcinoma |
| 03/07/2006 | US7008942 Cytotoxic agents comprising taxanes and their therapeutic use |
| 03/07/2006 | US7008934 For minimizing promethazine hydrochloride interactions with plasma proteins; injectable solutions |
| 03/07/2006 | US7008927 Pralmorelin-containing nasal drop preparations |
| 03/07/2006 | US7008923 Glycopeptide phosphonate derivatives |
| 03/07/2006 | US7008920 comprising pharmacologically active substance, drug absorbefacient and taurine compound or polyamine; suppressing or preventing damage of the intestinal mucous membrane |
| 03/07/2006 | US7008791 Liposome-entrapped DNA oral vaccines |
| 03/07/2006 | US7008648 Solvent extraction, distillation biomass |
| 03/07/2006 | US7008647 Treatment of acne |
| 03/07/2006 | US7008646 Comprising encapsulating compound, amphiphile capable of forming a cubic liquid crystalline phase, and optionally a solvent; powders that form cubic liquid crystalline particles on hydration |
| 03/07/2006 | US7008645 Bisphosphonate compound |
| 03/07/2006 | US7008643 Delivery system for biological material |
| 03/07/2006 | US7008640 Mixture of drug, aminoacrylate polymer and acid |
| 03/07/2006 | US7008639 Fish gelatin compositions containing a hydrocolloid setting system |
| 03/07/2006 | US7008637 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder |
| 03/07/2006 | US7008634 includes growth factors and extracellular matrix molecules flexibly tethered to a support medium; used to stimulate cell and tissue growth by enhancment of the biological response to the growth factor; liver cells |
| 03/07/2006 | US7008633 Injection of a biocompatible polymer, polysaccharide or polyamino acid, a cross-linker, and therapeutic agent into tumor; hydrogel formed in the tumor retains the therapeutic agent |
| 03/07/2006 | US7008628 End modified thermal responsive hydrogels |
| 03/07/2006 | US7008624 IL-15 or muteins covalently bound to group (PEG, PVP,PVA, dextran, gelatin) that sterically interferes with signal transduction through IL-15 receptor complex; allograft rejection and graft-versus-host disease |
| 03/07/2006 | US7008619 Methods of use and of making a mascara comprising at least one coloring agent and at least one polyamide polymer chosen from the ethylenediamine/stearyl dimer tallate copolymer |
| 03/07/2006 | US7008616 Ephedrine or fenfluramine; aluminum foil coated with a thin layer of drug is heated to form vapor; which condenses to form aerosol; rapid peak plasma concentration |
| 03/07/2006 | US7008615 Delivery of anti-migraine compounds through an inhalation route |
| 03/07/2006 | CA2332983C Sitostanol formulation with emulsifier to reduce cholesterol absorption |
| 03/02/2006 | WO2006023207A2 Coacervate of anionic and cationic polymer forming microparticles for the sustained release of therapeutic agents |
| 03/02/2006 | WO2006022887A1 Nanocoating for improving biocompatibility of medical implants |
| 03/02/2006 | WO2006022616A1 Methods and compositions for controlling parasitic infections of animals |
| 03/02/2006 | WO2006022340A1 Composite fine particles and process for producing the same |
| 03/02/2006 | WO2006022325A1 Galactose derivative, drug carrier and medicinal composition |
| 03/02/2006 | WO2006022301A1 Liquid preparation of physiologically active peptide |
| 03/02/2006 | WO2006022187A1 Coenzyme q10-containing composition |
| 03/02/2006 | WO2006021710A1 Polyamino acids functionalised by hydrophobic grafts bearing an anionic charge and applications thereof, such as therapeutic applications |
| 03/02/2006 | WO2006021706A1 Branched polyaminoacids, functionalized by hydrophobic groups and uses thereof in particular in therapy |
| 03/02/2006 | WO2006021643A1 Vaccine composition against rhodococcus equi |
| 03/02/2006 | WO2005107387A3 Targeting of radioimagining and radiotherapy agents |
| 03/02/2006 | WO2005105041A3 Methods of enhancing solubility in water of hydrophobic compounds by micellar dispersions |
| 03/02/2006 | WO2005100990A3 Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2) |
| 03/02/2006 | WO2005092929A8 Hyaluronic acid butyric esters with a low degree of substitution, procedure for their preparation and use |
| 03/02/2006 | WO2005086763A3 Stable injectable compositions |
| 03/02/2006 | WO2005072088A3 Immunotherapy compositions, method of making and method of use thereof |
| 03/02/2006 | WO2005019429A3 Compositions and methods for enhancing phagocytosis or phagocyte activity |
| 03/02/2006 | WO2004110423A8 Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine |
| 03/02/2006 | WO2003031464A3 Remodeling and glycoconjugation of peptides |
| 03/02/2006 | US20060047067 Novel electroconductive polymers |
| 03/02/2006 | US20060045906 Compositions and methods for activating protein synthesis and deactivating catabolic processes in skeletal muscle |
| 03/02/2006 | US20060045905 Composition for repressing transformation growth factor beta |
| 03/02/2006 | DE19916896B4 Teilchen mit kleiner Dimension, die eine Wand aus einem Gemisch von vernetzten Proteinen und Polysacchariden aufweisen, die an der Oberfläche mit Metallionen chelatbildende Hydroxamgruppen enthalten, Verfahren zu ihrer Herstellung und ihre verschiedenen Verwendungen insbesondere in der kosmetischen, pharmazeutischen und Nahrungsmittelindustrie Particles having smaller dimensions, which have a wall composed of a mixture of cross-linked proteins, and polysaccharides containing on the surface with metal ions chelating hydroxamic groups, process for their preparation and to their different uses, particularly in the cosmetic, pharmaceutical and food industry |
| 03/02/2006 | DE102004042139A1 Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit Oral dosage forms for obtaining a Retardierungseffektes after drug intake with a meal |
| 03/02/2006 | DE102004041496A1 Hydroxybenzoesäureamide und deren Verwendung zur Maskierung von bitterem Geschmack Hydroxybenzoesäureamide and their use for masking of bitter taste |
| 03/02/2006 | CA2578015A1 Crystalline maltitol powder less prone to consolidation and method for production thereof |
| 03/02/2006 | CA2576552A1 Eye drops for the treatment of dry eye |
| 03/02/2006 | CA2576473A1 Liquid preparation of physiologically active peptide |
| 03/02/2006 | CA2575407A1 Nanoparticles and method for the production thereof |
| 03/02/2006 | CA2574516A1 Vaccine composition against rhodococcus equi |
| 03/02/2006 | CA2574463A1 Nanocoating for improving biocompatibility of medical implants |
| 03/02/2006 | CA2573791A1 Branched polyaminoacids, functionalized by hydrophobic groups and uses thereof in particular in therapy |
| 03/02/2006 | CA2573612A1 Polyamino acids functionalised by hydrophobic grafts bearing an anionic charge and applications thereof, such as therapeutic applications |
| 03/01/2006 | EP1630136A1 Surface-modified titanium dioxide fine particles and dispersion comprising the same, and method for producing the same |
| 03/01/2006 | EP1629852A2 Topical anaesthesia formulation for bodily cavities |
| 03/01/2006 | EP1629846A2 Topical use of probiotic bacillus spores to prevent or control microbial infections |
| 03/01/2006 | EP1629842A1 Topical application of thiazolyl amides |
| 03/01/2006 | EP1629833A1 Process for producing microparticle |
| 03/01/2006 | EP1629832A1 A pharmaceutical formulation comprising human growth hormone, an amino acid and a non-ionic detergent |
| 03/01/2006 | EP1629105A2 Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| 03/01/2006 | EP1628991A2 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like protein |
| 03/01/2006 | EP1628986A2 Synthesis of high molecular weight iron-saccharidic complexes |
| 03/01/2006 | EP1628750A2 Stabilized particle dispersions containing surface-modified inorganic nanoparticles |
| 03/01/2006 | EP1628687A2 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 03/01/2006 | EP1628686A2 Spacer moiety for poly (ethylene glycol)-modified peptides |
| 03/01/2006 | EP1628685A2 Antiviral phosphonate analogs |
| 03/01/2006 | EP1628684A2 Complexing of medicinal substances with high-molecular strength |
| 03/01/2006 | EP1628683A2 Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
| 03/01/2006 | EP1628659A1 Use of poly-aminopyrrolecarboxamides alone or in combination with a cyclodextrin in the prophylaxis and treatment of animal parasitosis |
| 03/01/2006 | EP1628655A2 Antiseptic compositions, methods and systems |
| 03/01/2006 | EP1628645A1 Stabilized aerosol dispersions |
| 03/01/2006 | EP1628643A2 Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom |
| 03/01/2006 | EP1628635A2 Stabilized particle dispersions containing nanoparticles |
| 03/01/2006 | EP1628621A2 Polymeric conjugates for tissue activated drug delivery |
| 03/01/2006 | EP1628620A2 Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
| 03/01/2006 | EP1628618A2 Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| 03/01/2006 | EP1453523B1 Heparin-containing ophthalmic agent |
| 03/01/2006 | EP1446119B1 Compositions comprising ipatropium and xylometazoline for treatment of the common cold |